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Executive Summary 
The Opportunity  
The pathology industry has an impact on seventy percenti of medical decisions made,  
yet this industry is burdened by errors and inefficiencies. Mistakes in surgical pathology 
laboratories cost labs and insurance companies approximately $2.1 billion every year in the 
United States aloneii.  Mislabeling of tissue samples and contamination of specimens, which are 
common sources of pathology lab errors, result in improper diagnoses, leading to unreported 
cancers and unnecessary surgeries and painful treatments. Lawsuits resulting in awards of up to 
$3 millioniii have been reported just from problems with tissue sample handling. Most important, 
nearly seven million laboratory cases a year contain an error that could harm the patient.iv 
In addition to patient harm due to misdiagnoses, manual handling of tissue samples can 
produce personnel stress on pathology laboratories. The number of pathologists’ assistants (PAs) 
is expected to decline and demand for them to growv in the next two decades as a consequence of 
our aging population. The decreased supply of PAs and increased demands on them are likely to 
lead to a higher tissue handling error rate in the future.vi Automation is a way to address both 
issues: it decreases human errors due to manual handling of tissue samples and also allows 
pathology labs to handle more samples with fewer employees.  
The mission of BioBotic Solutions is to eliminate inefficiencies and errors in pathology 
laboratories. As a first step, we are introducing the PathOne and our patent-pending BioBox, 
which together will automate the manual transfer of biopsy tissue specimens in pathology 
laboratories.  The $300 millionvii annual market for the consumable specimen transport 
containers and biopsy bags that the BioBox will be replacing is growing at approximately 5% 
CAGR per year.viii 
Product and Competitive Advantage 
Our solution consists of two components that work together:  the PathOne machine and 
the consumable BioBox.  To minimize capital requirements, we are following the “Xerox 
model:” we are partnering with a manufacturer to develop, manufacture, distribute, and service 
the PathOne, while we focus our efforts on our patent-pending BioBox.  The PathOne consists of 
(1) a robotic arm that transfers tissue samples from the BioBox to a cassette (a small container), 
(2) an automatic bar code labeler, and (3) a conveyor belt that moves the tissue from initial 
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Figure 1: BioBox 
reception in the lab to a container where it awaits transfer to the diagnostic area of the lab.   
The PathOne will greatly reduce the time needed to perform the current labor-intensive and 
error-prone tissue labeling and transfer process. 
The BioBox replaces the separate containers and biopsy bags that are currently used to 
handle tissue samples with a single container that includes both.   
By combining these two separate components into one (see Figure 1), the 
tissue sample never leaves the biopsy bag once a surgeon has placed it in the 
BioBox in the operating room.  This reduces the risk of cross-contamination of 
tissue samples, which accounts for about two-thirds of specimen errorsix.    
The BioBox was invented by a pathologist at the University of Arkansas for 
Medical Sciences (UAMS) who saw the inefficiencies in the current method 
for tissue sampling employed in pathology labs. A prototype has been 
developed at the University of Arkansas by a team of biomedical engineers led 
by our CTO. 
Management Team 
Our management team is diverse and has expertise in pathology, entrepreneurship, 
finance, chemistry, and engineering. Our Interim Chief Executive Officer and Chief Financial 
Officer, Michael Iseman, is an honors Finance major at the University of Arkansas (UA). Rachel 
Zweig, our Chief Operating Officer, is a Mathematics and Chemistry major at Hendrix College. 
Our Chief Technology Officer, Kelley Coakley, is a Biomedical Engineering major at UA and 
led the development of the prototype for the BioBox. Maria Driesel, our Chief Business 
Development Officer is a Master’s candidate in Engineering Management and was a scholar of 
the Manage&More Qualification Program for Entrepreneurs in Munich, Germany.  
Dr. Shree Sharma, a medical researcher and pathologist at the University of Arkansas for 
Medical Science (UAMS) and the inventor of our technology, will serve as Chief Scientific 
Officer. We are seeking a permanent CEO with extensive experience in the pathology industry 
and a Director of Sales and Marketing. 
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Offering, Financial Summary & Exit Strategy 
We are currently seeking seed funding of $400,000 in the form of convertible debt to 
finish developing and testing our prototype and to hire a permanent CEO. We will be seeking an 
additional Series A funding round of $750,000 in 2015 to fund the cost of validating our initial 
units and acquiring initial customers. Series B funding of $1 million will be sought in January 
2016 to penetrate the market and provide operating capital for growth. 
 
Table 1: Investment/Funding Rounds 
Investment Amount Structure Timing Uses 
Angel $400,000 Convertible Debt May 2014 Business & Product Development 
Series A $750,000 Preferred Equity January 2015 Validation and Customer Development 
Series B $1,000,000 Preferred Equity January 2016 Production and Market Penetration 
 
We have identified multiple international medical manufacturers as potential acquirers of 
our technology. Becton Dickinson, Copan and Roche all provide automation solutions to the 
pathology industry and have a history of acquiring growing companies similar to BioBotic 
Solutions. Becton Dickinson’s earnings statements show an average of $250 million spent on 
acquisitions over the past four years, and Roche recently acquired BioImagene, an innovative 
leader in the field of digital pathology workflow and analysis, for $100 million in its 6th year of 
operation. Based off of an 8x EBITDA plus cash multiple, which is significantly less than the 
industry average of 20x earnings, and including discounted future earnings under contract, 
BioBotic Solutions will be valued at $80 million at the start of 2019.  This offers a return of 36x, 
26.5x, and 8x to Angel, Series A, and Series B investors, respectively.  
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Company Overview 
History and Current Status 
Pathologists handle the majority of the behind-the-scenes work in the medical field.  
Although they have very little patient interaction, they play an important role in the tissue 
examination that leads to 70% of all disease diagnosesx. BioBotic Solutions’ area of focus in the 
pathology industry is that of specimen grossing. Grossing is the entirely manual process of 
transferring a tissue sample from a container into a biopsy bag, which is then placed in a cassette 
(small container) before being sent off for processing and diagnosis.  
The pathology industry currently faces three major issues: inadequate quality control, 
such as mislabeling of specimens and contamination, insufficient laboratory staffing, and 
financial constraints. Seeing these problems in the lab, Dr. Shree Sharma invented a solution that 
addresses each of them.  Dr. Sharma is employed at UAMS, which filed a patent application for 
the BioBox (U.S. patent application #20/120,220,044) in 2012. The filing attorney, Blake 
Glasgow, of Wright, Lindsey & Jennings LLP, has been recognized by Mid-South Super 
Lawyers in the field of intellectual property. To move his solution from an idea to the market, 
Dr. Sharma reached out to the University of Arkansas for assistance in developing the prototype 
and the business. 
 BioBotic Solutions was founded by undergraduate students at the University of Arkansas 
and Hendrix College in the fall of 2013. We have made significant process in advancing the 
technology after speaking with potential customers, the FDA, robotic manufacturers, medical 
supply manufacturers, and industry experts. We hold an exclusive option on an exclusive license 
for the technology from UAMS BioVentures. To develop the prototype, we partnered with a 
team of UA biomedical engineering students, led by CTO Kelley Coakley. We are seeking seed 
funding for the prototype development of our robotic system, the PathOne, and for hiring a 
permanent CEO. 
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Figure 2: Goals, Objectives, and Strategies 
Mission and Vision  
Recognizing the need to decrease errors in the tissue handling process and save the 
pathology industry both time and money, our mission is: 
“to develop technologies that automate the pathology laboratory to increase efficiency and 
decrease both costs and errors that lead to misdiagnoses.” 
We envision that our tissue handling process will be the industry standard by 2021. 
Goals, Objectives and Strategy 
In order to realize our vision of becoming the ind stry standard and achieving our sales 
goals, we have developed a detailed 
outline of our objectives and 
milestones. Our core strategy is to 
outsource production, distribution, and 
servicing of the PathOne, while 
focusing on sales of the BioBox. We 
will maintain close contact with our 
end users to meet their needs with our 
customer-driven solutions. To minimize 
capital outlays, we will follow a “Xerox 
model.”   
We will sell the PathOne and BioBox 
via   
reagent rental agreements with pathology 
labs.  With a reagent rental agreement, 
Multi-Craft Contractors, or our chosen 
manufacturer, will install the PathOne at no or low cost to the lab.  Labs will then be charged a 
premium for each BioBox purchased.  The price of the BioBox will depend on a lab’s projected 
volume.  For a lab processing 40,000 samples a year, each BioBox will be priced at $5.00.  
The pathology labs will also pay our manufacturer $10,000 per year for the service agreement, 
which is typical in the industry.  After talking with pathologists, we have concluded that this is 
the most viable sales strategy, as labs will be more willing to purchase the equipment if it does 
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not require a large upfront capital investment. The milestones associated with each round of 
funding are outlined in Figure 2.  
Product  
 
Features and Current Stage of Development 
Most pathology laboratories are privately owned and independent of hospitals.  
Pathology laboratories send containers for biopsy samples to hospitals that have contracted for 
their services. The containers are sent in bulk to the hospitals, and the surgeon, nurse or other 
qualified personnel selects the appropriate container for the biopsy before surgery. After surgery, 
the container with the sample is returned to the lab.  
Our innovation consists of two products: (1) the PathOne, which is a robotic system 
placed at the front end of laboratory to automate the manual specimen labeling and handling 
system currently used in labs and (2) the BioBox, which will replace the container sent to the 
hospital and the biopsy bag into which the tissue sample is manually placed in the lab. 
 
The differences between the manual grossing process and the automated PathOne 
grossing process are outlined in Table 2. 
 
 
 
 
Figure 3: Pathology Workflow 
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Table 2: Comparison of the Status Quo and the PathOne 
 
Status Quo PathOne 
PA receives tissue in container PA receives tissue in BioBox and places it on PathOne 
conveyor belt  
PA labels cassette Barcode is scanned and printed on cassette 
PA removes tissues from container Robotic arm uncaps tube and removes bag 
Verbal description of the specimen HD camera photographs specimen in transparent bag 
PA places specimen in biopsy bag (Specimen already in biopsy bag) 
PA places bag in cassette Robotic arm places bag in cassette 
PA disposes of container in clinical waste PathOne discards BioBox in clinical waste 
 
Following this process, the cassette is sent to the diagnostic laboratory, an area of 
pathology that is already highly automated.  
PathOne 
The PathOne is an automated robotic system that is used at the front end of pathology 
laboratories. The small, approximately three-foot system can fit on a current lab station table and 
will not disrupt a lab’s workflow.  It is made up of a conveyor belt, a robotic arm, a storage 
container of different cassettes, a barcode scanner and printer, and a high definition camera.  
The cassettes are containers in which specimens are placed for further processing and are already 
used in the pathology industry; we will not be introducing new cassettes or replacing what is 
currently used. The robotic arm will have six degrees of freedom, and a special hand piece to 
handle the biopsy bag; this system may be the source for a future utility process patent 
application.  PAA Automation and Multi-Craft Contractors, both robotics manufacturers that 
have given us insight on their manufacturing process, have assured us that our system can be 
developed and manufactured with ease. The PathOne does not come in direct contact with tissue 
samples and requires no FDA certification.  
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BioBox 
Our patent-pending BioBox (see Figure 4) consists of a conical polypropylene test tube 
that includes an inset, transparent biopsy bag that is held in position by prongs on the inside of 
the test tube. The bag will be made of solvent resistant nylon (Industrial Netting: Catalog 
number: NN 3100 Nylon Mesh) that fits into industry-standard cassettes. A liquid preservative, 
10% neutral buffered formalin (Formaldehye 50-0-0), will be in the tube to ensure the specimen 
is fresh upon delivery to the laboratory.  
 
 
 
 
 
 
 
 
Figure 5: BioBox 
 
Figure 4: PathOne 
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The BioBox is a Class II device as defined by the United States Food and Drug 
Administration (FDA) and must meet the FDA’s Good Manufacturing Practices requirements. 
The BioBox prototype was designed in AutoCAD and has been 3D printed at the University of 
Arkansas.   Our next steps are to send our prototype to a manufacturer and work with them to 
produce the BioBox on a larger scale.   
Benefits 
We not only protect patients, but we also offer an affordable and timesaving solution to 
pathology laboratories, taking them one more step towards the 100% quality control program 
they have told us they want. In contrast to the current method of manual grossing, after the 
doctor places the tissue sample in the biopsy bag, the sample never leaves the bag again, 
meaning no chance of cross-contamination or specimen mix-up.  
During transfer from the BioBox to a cassette, a picture is taken by the PathOne to verify 
that the laboratory received the sample and to document the specimen; this will replace current 
inconsistent verbal specimen descriptions. In addition, the PathOne can operate 24/7, relieving 
the bottleneck that currently characterizes end-of-day operations. Pathologists at both NWA 
Pathology and UAMS have reported this as one of the biggest problems currently facing them 
and their laboratories. 
By automating the grossing process, PAs, technicians, and residents are available to do 
other important tasks within the laboratory that require analytical skills and cannot be automated. 
Staffing difficulties have been widely reported by the American Society for Clinical Pathology, 
and automation would eliminate the need for one or more of those positions, depending upon lab 
volume, helping to alleviate the staffing issue. 
We will also increase laboratories’ value proposition to their customers, the hospitals 
whose samples they process. Laboratories using the PathOne will have lower operating costs and 
can pass on their cost savings to hospitals and/or increase their profit. More important,  
these laboratories can advertise lower error rates and increase their revenues as the number of 
samples they process increases. Being able to differentiate themselves is especially important for 
labs in metropolitan areas, such as New York City and Los Angeles, which have over twenty 
pathology laboratories competing for business. 
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Competitive Analysis 
Our patent-pending BioBox, strategic alliance with UAMS, and relationships with 
pathology laboratories give us a strong competitive advantage. UAMS has agreed to host our 
pilot deployment of the PathOne to validate its functionality and reliability. Also, our inventor, 
Dr. Sharma, is well respected and has a large network within the industry. We have also 
developed a strong network as we have developed the business.  
We contracted with a third party market research firm, Invention Evaluator, to gain a 
further understanding of the industry and the feasibility of our solution. The report yielded 
favorable results, identifying our patent application as very useful, novel, and inventive, giving it 
a high probability of being granted and creating a strong barrier to entry for potential 
competitors. 
Furthermore, our position as an industry first mover is a competitive advantage. Being a 
first mover will allow our company to validate our solution and establish credibility with 
customers without the concern of any direct competitors.  Due to the length of time required for 
validation, we anticipate being able to sell to pathology laboratories before competing 
technologies are ready for purchase.  In addition, the length of the contract for reagent rental 
agreements, typically three to five 
years, will allow us to evaluate 
the PathOne, improve it based on 
customer feedback, and deepen 
our relationships with pathology 
laboratories. 
Finally, our system offers 
a variety of advantages in 
comparison to our indirect 
competitors in the market, as seen 
in Table 3 and Figure 5.  Our 
direct competition is the status 
quo of manual handling, which 
we have described above.   
Figure 5: Market Advantages 
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A third-party research firm has done a patent search on our technology and verified that 
there are no directly competing technologies on the market or in the pipeline today. Automation 
technologies are available for other processes in the pathology laboratory, and the PathOne 
would integrate with these to help streamline the laboratory workflow. Upon an issuance of a 
patent for the BioBox, there will be even greater barriers to entry for other laboratory robotic 
manufacturers. 
An indirect form of competition is DNA matching analysis, which can be used to catch 
specimen mix-ups after they occur, but this is costly, time consuming, and catches mistakes 
rather than prevents them. KnowError is an example of a company providing this service;  
after taking a swab sample of the patient’s cheek, they match it with the DNA of the biopsy if the 
sample comes back positive.  DNA matching analysis is seldom used, however, due to the high 
cost-about $1500 per case-and labor needs and increased turnaround time.xi 
Table 3: Product Advantages 
Advantage BioBotic DNA Matching Manual Handing 
Staff Needed 0 ≥2 2 
Cost per Sample  $5 $200-$1500 $5 
Lower Chance of Specimen Mix-up !  !   
 
 
Market and Competitive Analysis 
Market Overview  
The annual market for the consumable specimen containers and biopsy bags that the 
BioBox will replace is worth about $300 million today, and the number of biopsies performed 
each year is increasing at a CAGR of 5% xii.  Revenue for anatomic pathology labs, which are 
responsible for grossing biopsy specimens, grew 16% from 2006-2009.xiii  These point to a 
growing market for biopsies and the consumable products used in them. 
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Driving Forces 
With worldwide trends such as an aging population, increasing cancer rates, and a larger 
focus on health care, pathology laboratories are processing more specimens than ever before. 
Among Medicare enrollees, the number of biopsies performed increased at a compounded annual 
growth rate of 3% between 1997 and 2008.xiv Technological advances are playing a large role in 
the world’s leading industrial countries, and automation has replaced many manual processes, 
such as in vitro diagnostic systems. We have identified three industry-specific forces that provide 
an opportunity for BioBotic Solutions. 
Quality Control: Mislabeling and Cross-Contamination 
Human errors during the manual grossing process include the mislabeling of specimens, 
cross-contamination, and spillage or losing small tissue samples during the transfer from the test 
tube to the cassette. Washington University and the American Journal of Clinical Pathology have 
conducted studies of errors committed during the routine pathology process. These studies 
examined over 13,000 specimens and found error rates of 3% and 0.93%, respectively. 
Assuming 0.93%, the low end estimate, a midsize lab processing 40,000 samples in a year will 
make 370 preventable mistakes per year. The Institute of Medicine reported that 70% of 
specimen-identification errors happened in the gross room.xv Errors that are caught can cause lab 
staff to spend fifteen to forty-five minutes correcting the mistake. xvi, xvii Six percent of errors,  
or nearly 4 million cases a year, lead to patient harm, which demonstrates a need for an error-free 
solution.xviii  
Human Resources: Lack of Laboratory Personnel 
In its Wage and Vacancy Survey of Medical Laboratories, the American Society for 
Clinical Pathology found that 43% of laboratories reported difficulties hiring personnel,  
which they attributed to underqualified applicants, retirement, and high turnover.xix  
Quest Diagnostics, which employs about 8,500 lab professionals, making it one of the nation's 
largest lab companies, currently has about 1,200 job openings nationwide, illustrating their 
staffing problem.xx 
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When labs face a high volume of specimens to gross, they either use less qualified 
personnel or improvise by pulling staff from other work areas and asking technicians to work 
double shifts. Not only does this put a strain on the laboratory, but it also increases the risk for an 
error by having under-trained and overworked employees in the gross room.  
The PathOne will free up PAs to gross larger tissue samples and specimens that require 
special orientation or manipulation before being tested. These tasks cannot be automated and 
require the expertise of a trained PA. Sixty percent of the tissue samples that labs typically 
receive, however, will be able to be grossed by our solution.  
Financial Constraints: Decreased Reimbursements 
Due to the expiration of the Technical Component (TC) Grandfather Clause and recent 
healthcare reforms, federal reimbursements to labs for the Current Procedural Technology (CPT) 
code for the grossing of small biopsy specimens decreased by 52%.  From 1999 to 2012, the TC 
Grandfather Clause provided reimbursement to pathology laboratories for much of the clinical 
work done in the lab,xxi but that reimbursement rate has now ended.  Pathology labs are not 
getting compensated for this lost revenue elsewhere.  As a result, they are desperate for cost-
saving measures, such as the PathOne and BioBox. 
Market Acceptance 
Due to these driving forces, pathology laboratories will have a strong need to adopt new 
automation technologies. The pathology industry has a bias towards the status quo of manual 
tissue handling. Pathologists with whom we have talked, however, recognize inefficiencies in 
grossing and are excited about our technology.  Pathologists drive the purchasing decisions in 
most labs and are the decision makers in independent laboratories; once new technologies have 
been validated and shown to be reliable and effective, they can make purchasing decisions in a 
monthxxii.  To encourage rapid adoption of our technology, we will be building the cost of the 
PathOne into the consumable BioBox.  This approach is very common in the industry and is 
widely accepted by pathology labs. 
The average salary of a pathologist’s assistant is $73,000, and that of a lab technician is 
$42,000 to $49,000iv. Laboratories currently pay $3.35 for the containers and biopsy bags used to 
process a specimen. The BioBox will replace these disposables, and will also remove the labor 
cost associated with grossing each specimen. With our integration, labs will be able to eliminate 
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or avoid hiring the equivalent of one to two full time positions. Even a lab on the conservative 
end of our target market, one processing 40,000 samples per year, will experience an immediate 
cost reduction due to personnel savings.  
Management Team 
Management Profile 
Dr. Shree Sharma: Chief Scientific Officer 
Dr. Shree Sharma has been working as an Assistant Professor in the Department of 
Pathology at the UAMS since 2012. He finished his pathology residency from one of the premier 
institutes in India (AIIMS, New Delhi) before moving to the United States in 2007.  
He specializes in renal pathology and finished his fellowship from Columbia University Medical 
Center in New York in 2012 Dr. Sharma is interested in integrating technology into the  
day-to-day workings of the laboratory to improve patient care. He has more than 25 publications 
in peer-reviewed journals and book chapters and has presented many abstracts and posters at 
national and international conferences. . Leica recently telecasted his webinar on mobile 
technology in pathology. Dr. Sharma is a member of many pathology organizations, including 
the Innovation Educational Products Committee of the United States and Canadian Academy of 
Pathology (the biggest pathology organization in U.S. and Canada). Dr. Sharma is a young, 
energetic pathologist and sees opportunities to treat problems that have long gone unaddressed in 
pathology labs; that passion led him to invent our technology. 
Michael Iseman: Interim Chief Executive Officer and Chief Financial Officer 
Michael Iseman is a senior at the University of Arkansas, where he studies Finance and 
Spanish. He spent a semester studying business and Spanish in Spain and speaks Spanish 
fluently. He served as an intern at the ARK Accelerator, a startup accelerator providing young 
technology and retail startups the resources they need for success. At the ARK, he gained 
exposure to the practical steps needed for cost-effective early business development.  
He currently works as an associate at Elevate Performance, a consulting firm providing 
leadership development resources to the CEOs of Northwest Arkansas businesses through CEO 
Forums. There, Michael has established a powerful network with the more than forty regional 
leaders in business, and gained exposure to the issues and opportunities facing a C-Suite 
executive. 
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Rachel Zweig: Chief Operating Officer 
Rachel Zweig is a sophomore at Hendrix College and is pursuing a double major in 
Chemistry and Mathematics. She is co-captain of the Hendrix women's soccer team and made 
the Academic All-District Team in 2013. Rachel is an Arkansas Governor's Distinguished 
Scholar and was a National Merit Finalist in 2012. She worked in her family’s small business for 
many years and has pursued her own entrepreneurial endeavors since she was 10.  
Kelley Coakley: Chief Technology Officer 
 Kelley Coakley is a senior at the University of Arkansas studying Biomedical 
Engineering and Mathematics, with a Sustainability Minor. She is on the premedical track and 
has been accepted into UAMS, where she will start medical school in the fall of 2014.  
Kelley has been participating in research at the UA for three years and leads the team of 
biomedical engineers developing the BioBox.  
Maria Driesel: Chief Business Development Officer 
Maria Driesel was born and grew up in Germany. She is studying Engineering 
Management at the Technical University of Munich with a focus in Innovation, Entrepreneurship 
and Project Management. As a fellow of the 18-month Manage&More Qualification Program 
she gained extensive knowledge in entrepreneurship. Manage&More focuses on working in 
interdisciplinary teams as well as developing and implementing business concepts to create 
innovative and marketable products and services. As a participant of this program, Maria applied 
her education to innovation projects with BMW Group and Bosch. In addition, she gained a lot 
of experience in project management with her work at IMP Management GmbH, where she 
worked in the field of office space planning.  
Future Needs and Compensation 
The first key hire for BioBotic Solutions is a CEO with extensive experience in both the 
pathology industry and lab automation equipment industry. In 2015, we anticipate hiring a 
Director of Sales and Marketing to lead customer development as the PathOne finishes 
validation and becomes market-ready. The Director of Sales and Marketing will lead the 
management team in securing our first five accounts in 2016. 
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The current management team will be compensated with an annual salary of $25,000, 
growing at 7% beginning in 2015. Once the permanent CEO has been hired, he or she will start 
with an annual salary of $150,000. Both the management team and the CEO will be compensated 
with equity distributions based on longevity and the achievement of both personal goals and 
company milestones. Provided that all goals are met, equity will be distributed to the CEO at a 
rate of 2% semiannually and to the management team at a rate of 0.5% semiannually.  
This agreement will expire and management benefits will be reevaluated after three years, in 
2017, with a maximum of 24% ownership distributed as compensation. 
Board of Advisors 
Table 4: Board of Advisors 
 
Advisor/ Position/ 
Company Focus Qualifications 
Thomas Blodgett 
Director of Operations 
Multi-Craft Contractors 
Inc.  
Automation and 
Robotics 
• Developed A&R program at Multi-Craft Contractors 
• Served as the director of project development 
Jared Greer 
Medical Device Sales 
Rep. 
Medtronic 
Medical Device 
Sales 
• 10+ years’ experience in medical sales 
• Co-founder and CEO of Tears for Life, a medical start-up 
• Medical sales channel knowledge and experience 
Lucas K. Campbell, M.D. 
Partner and President  
Northwest Arkansas 
Pathology  
Pathology 
Laboratories 
• 11+ years’ experience in the pathology industry 
• 4 years’ experience on hospital committees 
• Purchases medical equipment for NWA Pathology 
Paul Mlakar 
Senior Executive 
Blackstone Construction, 
LLC 
Medical Start-ups 
• 13+ years’ experience in start-up, strategy, and improvement 
• Raised $3.3 million in start-up funding for medical start-up 
• Founded 4 companies 
• Operations Manager of construction start-up; increased sales 
from $6m to $50m in 4 years 
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Operating Strategies 
Validation 
 In order to validate our technology, we will run six-month trials at three beta sites of 
various sizes: laboratories with high, medium, and low volume of biopsy specimens. We will 
first run dummy samples and then progress to discarded tissue samples before running tissue 
samples intended for diagnosis. After manufacturing, no additional cost will be incurred to run a 
beta site in the UAMS pathology laboratory due to their vested interest in the success of the 
venture. For the other sites, we will negotiate with the laboratories to find a suitable payment 
arrangement. Two possibilities are giving the laboratory equity in BioBotic Solutions and giving 
the laboratory a discounted rate on the BioBox for one to two years. 
Production 
After validation is complete, we will outsource manufacturing, distribution, and servicing 
of the PathOne system to minimize capital requirements. Multi-Craft Contractors has expressed 
interest in manufacturing the PathOne and has the capabilities to distribute and provide 
aftermarket service for the PathOne. We will provide our customers with a warranty, technical 
support, maintenance, inspections and upgrades for our system through BioBotic Support,  
which Multi-Craft will operate and manage. This service arrangement is typical within the 
industry.  
To produce the BioBox, we will contract with a manufacturer, such as Fisherbrand,  
that has established distribution channels within the pathology industry. We will negotiate a 
supply agreement with the manufacturer. 
Sales and Marketing Strategy 
Our initial sales and marketing strategy is to target laboratories with a high volume of 
specimen samples (more than 40,000 biopsy samples annually) and those that are in regions with 
an acute labor shortage, such as the Western U.S. We also plan to focus on high-end laboratories 
that can become leaders and best-practice examples for new technology.  
We will initially focus on the U.S. market, which accounts for the largest market share of 
lab automation equipment and consumables. Our next step will be an expansion into Canada, 
which has the same certification requirements as the United States. After gaining traction in 
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North America, we will open operations in the European and Australian markets, where 
laboratory automation is appealing due to stringent laboratory accreditation requirements.  
After talking with pathologists and purchasing decision-makers in pathology labs,  
we have identified three key way to market our technology. First, we will raise product 
awareness at pathology conferences and trade shows and visit labs, where we will demonstrate 
our technology and expand our network within the industry.  Second, we will conduct efficacy 
studies during the validation of the PathOne and publish the results in pathology trade journals, 
such as Modern Pathology, Critical Values and AJCP.  Pathologists have told us this is critical in 
order to gain market acceptance.  Finally, pathologists have told us that after our technology has 
been verified, it will spread by word-of-mouth.  After our initial market penetration our 
management team will continue advertising, giving lab demonstrations, and exhibiting at trade 
shows. 
In 2015 we will hire a Director of Sales and Marketing to lead our customer development 
process and increase market awareness as the PathOne finishes validation. The management 
team and director of sales and marketing will act as our sales force in 2016, when we project 
selling to our first five accounts. After this initial market acceptance, we plan to contract with a 
medical distributor to represent our product to labs. Medical distributors will have proven sales 
channels and preexisting relationships with the laboratories. 
Research and Development 
 Our R&D team will seek to improve on our existing technology to make the grossing 
process more efficient. We will work on new solutions to improve the workflow in the pathology 
lab, such as a way to automate the decalcification process for bone marrow.  We anticipate 
applying for both domestic and international patents for new intellectual property created in our 
labs, and have included patenting expenses under research and development in our financial 
projections. 
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Risk Management 
As with any new company, risks must be anticipated and mitigation plans adopted.  
We have identified several risks that we may encounter and developed mitigation plans for each 
of them. 
Table 5: Risk Management 
 
Risk Explanation Threat Level Impact Level 
Market Adoption Slow adoption High Moderate 
Validation System not validated Low High 
Warranty System requires frequent servicing Low High 
Patent issuance Patent still pending Moderate High 
Competition Established competitors Moderate Low 
Political Health care policy change Low Low 
Financial Yet to raise capital Moderate High 
Management Team Need to hire qualified management team Moderate High 
Product Additional development and validation of 
PathOne and BioBox needed 
Low High 
 
Market Adoption 
Pathology is typically the last sector of the healthcare industry to adopt change.  
Initial conversations with pathologists, however, have demonstrated that once we can show 
PathOne is reliable and efficient, pathologists are interested in bringing PathOne into their labs. 
In addition, the number of pathologists is forecasted to decrease significantly after 2014, 
resulting in an increased need for automation in the lab. Labor restrictions and stringent 
accreditation requirements in Europe make it likely that European laboratories will readily adopt 
our systemxxiii.  
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Validation 
We will test the PathOne at three beta sites with varying sample volumes for six to twelve 
months and make necessary changes to optimize the reliability and effectiveness of the PathOne. 
We will use these beta sites to conduct exhaustive studies and collect data on the effectiveness 
and integrity of PathOne and publish these in trade journals. We will also work closely with 
these labs to make incremental improvements, ensuring a one year validation. 
Warranty 
To decrease the need for extensive servicing of our system, we will perform multiple  
pre-market tests to ensure that our system will stand up to the rigors of pathology laboratories, 
which often process hundreds of samples a day. In addition, validation will require that our 
system is durable. We will continue to run testing sites so we can continuously make and 
monitor changes to the PathOne. This will ensure that service fee paid to BioBotic support will 
cover costs associated with servicing and provide our manufacturer with profit. 
Patent 
We anticipate being awarded a patent for the BioBox. Invention Evaluator,  
an independent firm, examined the patent and gave it a favorable outlook. If the patent is not 
issued, we will establish and build upon our reputation as a low error system and be ahead of the 
market as a first mover. Later, to protect against patent expiration, we will invest in R&D to 
expand our patent and file for a utility patent by making continual improvements to our system, 
including how to expand the tasks covered by the system. In addition, we will build brand equity. 
Competition 
There are currently no direct competitors to PathOne, and Google searches have not 
turned up any competing technologies in the pipeline, as verified by Invention Evaluator. 
However, we realize that other companies like us might be trying to take advantage of this 
opportunity. We will initially target areas with a high need for automation and then build upon 
established relationships and brand equity to move into other areas. We will use our service team 
and our established reputation as a low error system as key selling points. 
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Political 
The Affordable Care Act has resulted in a fifty-two percent decrease in reimbursement to 
pathology laboratories for the grossing of small biopsy specimens. The decreased funding makes 
our system more attractive. Another policy change could result in a higher reimbursement rate, 
but given the lack of political appetite to make more health care policy changes and the desire to 
cut government costs, this risk is low. 
Financial 
We are still seeking capital and will not be able to move forward with the product before 
finishing the development of our prototype. The funding we are currently seeking will be 
primarily used for prototype development. 
Management 
BioBotic Solutions is currently run by pathologist Dr. Sharma and a student management 
team; we fully anticipate bringing on an experienced executive and other managers as we 
validate our products.  We will hire an experienced CEO in the medical and health care industry 
to provide leadership to the company and a Director of Sales and Marketing. 
Product 
PAA Automation and Multi-Craft Contractors, two potential manufacturers of the 
PathOne, have assured us that the PathOne can be manufactured easily, and Multi-Craft has 
agreed to do R&D on the PathOne and make necessary modifications to address the needs of 
both pathology laboratories and manufacturing. The BioBox has been developed by a team of 
biomedical engineers at the UA, and they have identified the necessary material for the inset 
biopsy bag and the tube. We will work closely with the manufacturers of both the BioBox and 
the PathOne to ensure feasibility and make alterations as needed. We will communicate any 
changes in the manufacturing of the BioBox or the PathOne that may affect the design of the 
other product with the appropriate manufacturer to ensure compatibility. 
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Sources and Uses of Funds 
BioBotic Solutions is seeking a seed funding round of $400,000 from angel investors by 
May 2014 to finish prototype development and to hire a permanent CEO with experience in the 
medical device and pathology fields. UAMS will be a free beta site, and we will look to contract 
with two other labs of varying sizes to ensure rigorous product validation. By January 2015,  
we will seek a Series A round of $750,000 to fund customer development and sales and 
manufacture our initial units. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Sources and Uses of Funds Amount 
Seed Funding $400,000 
Patent Expenses $20,000 
PathOne Research & Design $100,000 
PathOne Development $100,000 
BioBox Development & Production $14,000 
Salaries and Wages 127,125 
Other Employee Costs $37,125 
Series A Round $750,000 
PathOne Research and Development $180,000 
BioBox Production $75,000 
Installation & Integration $30,000 
Salaries & Wages with taxes $210,750 
Marketing and Customer Development $12,000 
Series B Round $1,000,000 
Round will be utilized to manufacture initial units and fund selling, general, 
& administrative expenses in 2016. Investment will be supplemented by 
income from initial sales to finance operating expenses. 
Table	  6:	  Source	  and	  Uses	  of	  Funds	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Table 7: Investment/Funding Rounds 
Investment Amount Structure Timing Uses 
Angel $400,000 Convertible Debt May 2014 Business & Product Development 
Series A $750,000 Preferred Equity January 2015 
Validation and Customer 
Development 
Series B $1,000,000 Preferred Equity January 2016 Inventory and Market Penetration 
 
Offering and Exit Strategy 
 BioBotic Solutions is currently seeking angel funding for our seed round of $400,000 to 
be structured as a convertible note. Interest on the note will compound annually at 8%, and the 
note will convert to preferred equity upon the event of a Series A round, predicted to be in 
January 2015. The note will convert at a 25% discount to compensate investors for the additional 
risk taken on by investing in an early stage venture, and the conversion will cap at a $4 million 
valuation. We will pursue Series B funding in January 2016. These funding rounds will be 
allocated to product validation and customer development and will be structured as preferred 
equity.  
   The state of Arkansas offers attractive incentives for investors in new, knowledge-based 
companies such as BioBotic Solutions.  We will apply for approval for Equity Investment Tax 
Credits for Series A and B Investors.  These credits give investors a 33% credit of the amount of 
their investment on their Arkansas state income taxes.  For non-Arkansas investors, these credits 
can be sold.  We will also seek state funding from the Risk Capital Matching Fund and in the 
form of R&D tax credits.  We have not included funds from these sources in our financial 
statements, but they will reduce our investors’ risk and lower capital requirements should we be 
approved for them. 
After discounting projected revenues and comparing BioBotic Solutions to similar pre-
revenue firms, we predict a pre-money valuation of $3 million for Series A and of $10 million 
for Series B funding rounds. Dr. Sharma, the inventor, will begin with 10% equity,  
and incremental distributions will be made to the management team based on performance and 
tenure, as outlined in management compensation. The equity of BioBotic Solutions will be 
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divided into 100,000 shares, and Table 4 summarizes our anticipated equity breakdown after all 
rounds of funding in January 2017. 
 
Table 8: Projected Equity Distribution January, 2017 
 
Party Contribution Percent Equity 
UAMS Patent 5% 
Dr. Shree Sharma Invention 10% 
Management Team (combined) Labor 12% 
CEO Labor 12% 
Seed Investors $400,000 18.6% 
Series A $750,000 25% 
Series B $1,000,000 10% 
BioBotic Solutions Retained 7.4% 
 
Our primary exit strategy will be an acquisition by a large lab equipment manufacturing 
company after we have gained sales traction. It is common in this industry for smaller companies 
to be acquired after the market has accepted the technology.  Some recent acquisitions of small 
lab equipment companies by large lab equipment manufacturing companies can be seen in Table 
4. An alternative exit strategy would be to exit pre-revenue after Series A, but prior to Series B, 
at a projected valuation of $3 million, after the validation of our initial units.  Becton Dickinson 
has indicated an interest in pursuing technologies in the validation stage and taking them to 
market.  Although the returns for an earlier exit would be lower, a pre-revenue exit would give 
our investors a quicker return on their investment and reduce their risk. 
Table 9: Recent Lab Equipment Company Acquisition 
Company Acquired Price 
Becton Dickinson HandyLab $275m 
Roche Constitution Medical, Inc. $220m 
Roche Biolmagene $100m 
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Assuming a discounted industry average P/E ratio of 8, we assume a valuation of 8x 
earnings in 2018 plus 2x future earnings under contract. Future earnings under contract are a 
result of the reagent rental agreement 5-year contracts. Revenue under contract was discounted at 
20% to reflect the time value of money and an allowance for doubtful accounts and we assume, 
using a discounted industry average, that 15% of revenues will be retained as earnings.  
With these assumptions, and those outlined in the Notes to Financials, BioBotic Solutions will be 
valued at $80 million at the start of 2019. An acquisition at this point would yield a 36x return 
for Seed Funding Investors, 26.5x return for Series A investors, and an 8x return for Series B 
investors. 
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Appendix I: Pro-Forma Financial Statements 
Notes to Financials 
1. Revenue numbers include sales of 40,000 BioBoxes per year to each of our customers at 
an average price of $5.00.  Sales begin in 2016 with 5 laboratories.  After partnering with 
a national sales force, sales will grow to 50 laboratories in 2017, and increase to 200 
laboratories in year 2018.  
2. FDA certification for a Class II device will fall under the 510(k) guidelines, and will be 
$4,328. The cost is incorporated into Research and Development in 2014. 
3. UAMS will not receive royalties for sales of BioBox in the first three years of sale so that 
growth is not stifled. Instead they will retain 5% equity in BioBotic Solutions to 
compensate for patent usage. 
4. Research and Development in 2014 increases in months when payments are made to our 
manufacturing partner for PathOne development. . R&D expense in 2015 accounts for 
production and delivery of three PathOne units to be tested at validation sites. 
5. Based off of industry comparables, we assume manufacturing and distribution costs for 
the BioBox will be $2.18.  
Cost will decrease to $1.90 per Box as operations scale in 2017. 
6. Amortization calculated straight-line over the 20-year life of the patent. 
7. Accounts Payable assumes that 75% of payments are made in the current month, and 
25% in the following month. 
8. Accounts Receivable assumes that 60% of payments are received in the current month, 
25% in the second month, and 15% in the third month. Billing will be on a contractual 
level, and doubtful accounts are considered to be irrelevant.  
9. CEO will start with a salary of $150,000 and Management team at $25,000. As outlined 
in management compensation, these salaries are discounted and substituted with equity 
options. Director of Sales and Marketing will start at $150,000. All salaries are expected 
to increase at 7% annually. Salaries and wages do not increase at the scale of sales due to 
our sub-contracting of the sales force. Payroll Taxes are calculated as 7.65% of salary and 
wages. Benefits are calculated as 20% of salaries. 
10. Office Equipment accounts for computers, phones and other general capital purchases 
associated with operations and bringing on new employees, and will depreciate over a 4 
year useful life.  
11. PathOne units for use in lab demonstrations and trade show expositions are held as fixed 
assets and are depreciated straight line over a 5-year useful life. 
12. We estimate sales expenses of $100,000 in 2016 to compensate for travel and other 
customer acquisition costs. After 2016, we will partner with a large medical distributor 
with preexisting sales channels. We have allocated an additional 20% of total revenues to 
selling costs after partnering with a distributor which is represented in COGS. Additional 
costs are assumed to be in SG&A which is 10% of total revenues.  
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13. Annual payments to Multi-Craft, or selected PathOne manufacturer, are $20,000 per 
PathOne and accounted for in COGS. Service agreement fees are paid by the laboratory 
directly to the manufacturer, and will not affect our financial statements.  
14. R&D expenses are calculated on industry average of 8.8%, plus 10% for the years  
2016-2018. 
15. Inventory is not carried by BioBotic Solutions. MultiCraft Contractors will hold the 
inventory for the PathOne, and we will pursue a supply agreement with manufacturer of 
BioBox. 
16. Distributions of 33% of profits will be remitted to investors in April on years after profits 
are made so that members can make tax payments for the previous year. 
17. Due to the nature of the reagent renal agreements, each contract with a laboratory will 
initiate a 5-year revenue stream, or $200,000/year, for the BioBoxes. The portion to be 
collected within the coming fiscal year moves to accounts receivable. These contracts 
will represent $192,000,000 in future revenues at the end of 2018. Because the funds 
have not yet been received, and the service has not yet been performed, this is an off 
balance sheet account, and accounted for in the balance sheet footnote. 
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Income Statement 
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Statement of Cash Flow 
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Balance Sheet 
 
Off balance sheet account of future revenues under contract are $4 million in 2016, $43 million 
in 2017, and $192 million in 2018. 
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Appendix II: A Perfect Pattern Match 
“Pattern Match.” It’s more than just a buzz word. Through the art of pattern matching, 
and a lot of hard work, BioBotic Solutions was able to represent the University of Arkansas in 
achieving unprecedented success in undergraduate business plan competitions. This truly is an 
art, as it challenges the entrepreneur with a new, creative idea, to communicate it in terms that 
their audience, whether a customer or investor, is comfortable with and can understand. For one, 
people don’t always respond well to change, and most important, if it has worked well before it 
will likely work well again. 
The first step in effective pattern matching is to really understand your customer, and 
uncover all relevant industry information. It is important to know how disruptive your new 
technology is within the industry, and likewise, what are the most effective ways to incorporate 
your solution into the industry to optimize rather than disrupt the current work flow? Most 
importantly, what will make your customers most comfortable with purchasing your product? 
After identifying the best practices within the industry, the entrepreneur is charged with the task 
of communicating this to investors, who often are not familiar with the industry. We must 
communicate this new idea with investors in terms that they understand so they are able to 
clearly see the viability and investability of the business. If the idea is sound and communicated 
effectively, the probability of a successful venture begins to increase exponentially. 
One area in particular that we learned all aspects of the perfect pattern match was with 
our ever-evolving business model. We eventually concluded on using “reagent rental 
agreements” as our most effective strategy, which is essentially the “razor and blades” method 
(see what I did there? – that was a pattern match). Initially we structured our business model 
around a markup on the robotic equipment, and assumed the containers would be sold for 
pennies on the dollar. After pitching to investors who were confused as to where and how we 
would be making money, and receiving push-back from pathology laboratories, the business 
model was revisited. We found that pathology laboratories are hesitant to make large capital 
purchases due to their budgetary constraints and rapid advancements in technology within the 
industry. They are more comfortable spreading the cost over a number of years into their 
operating cash flows, and aren’t as concerned about owning the equipment. We were then tasked 
with incorporating this new information into our strategy, and communicating it with all parties. 
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We researched the reagent rental agreements, and they began to make sense. We would 
place the equipment in the laboratory at no cost to the lab. Then we determine how many of our 
containers that they would purchase per year, and set the price of the containers at a level that we 
can recover the cost of the robotic equipment, manufacturing and delivery of the containers, and 
retain a sufficient level of profits. This allowed us to better identify our initial target market, 
communicate to them where and how much money they will save, and we had structured our 
pricing strategy in a manner that they were most comfortable with. This was a win – win solution 
for both our company and our customers, now we needed to communicate it with the investors. 
This business model was somewhat complex, as we now had many players involved. 
Manufacturers for both the container and the robotic equipment and the container, a potential 
leasing partner, the laboratory and in some cases more were involved. Although the pathology 
laboratories were familiar with this model, most of our audience had never heard of a “reagent 
rental agreement,” and we struggled to communicate what we thought was a fantastic idea. We 
eventually realized, with the help of our brilliant advisors, that although the vocabulary might be 
new, the idea has been around since Xerox made huge profits by discounting printer sales and 
charging a markup for copies in the 90’s. Once we began to communicate this idea as “the Xerox 
method” or “the razor and blades method” we never had to worry about it as a friction point with 
investors or critics. 
The first step is having an idea, and it is crucial to do sufficient customer development, 
problem interviews and market research. Once that has been achieved it will be easier to tell 
whether or not your idea really solves a problem (if you can’t tell, then do more research). After 
establishing that you have a viable venture, communication is the most important step in 
progressing forward. We have found that the most effective way of communication is to meet 
people where they are, and speak in terms and ideas that they will understand. That is the art of 
the pattern match. 
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Appendix III: Contact Information 
Dr. Shree Sharma 
+1 (502) 052 6363 
sgsharma@uams.edu 
 
Michael Iseman 
+1 (816) 728 9331 
miseman@email.uark.edu 
 
Rachel Zweig 
+1 (479) 422 7518 
rezweig@gmail.com 
 
Kelley Coakley 
+1 (501) 844 7374 
kcoakley@email.uark.edu 
 
Maria Driesel 
+1 (281) 908 2374 
+49 173 91 07 498 
maria.driesel@manageandmore.de 
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